Efficacy of ivabradine in HIV-associated dilated cardiomyopathy

Area of Science:

• Cardiology
• Infectious Diseases
• Pharmacology

Background:

• Chronic heart failure (CHF) with systolic dysfunction affects numerous adults.
• Human Immunodeficiency Virus (HIV) infection can lead to cardiac complications like dilated cardiomyopathy.
• Ivabradine is a heart rate-lowering agent approved for specific CHF populations.

Purpose of the Study:

• To report the beneficial effects of ivabradine in an HIV-infected patient with dilated cardiomyopathy and NYHA class III CHF symptoms.
• To evaluate the impact of ivabradine on clinical parameters, functional capacity, and left ventricular (LV) systolic function.
• To identify potential drug interactions between ivabradine and antiretroviral drugs.

Main Methods:

• Case report of an HIV-infected patient with dilated cardiomyopathy and CHF.
• Administration of ivabradine to manage heart rate and CHF symptoms.
• Assessment of clinical parameters, functional capacity (NYHA class), and LV systolic function.
• Review of potential interactions between ivabradine and concurrent antiretroviral medications.

Main Results:

• Ivabradine improved the patient's functional capacity from NYHA class III.
• Significant enhancement in left ventricular (LV) systolic function was observed.
• Potential clinically significant interactions between ivabradine and antiretroviral drugs were identified, requiring monitoring.

Conclusions:

• Ivabradine demonstrated beneficial effects on clinical parameters and LV systolic function in an HIV-related dilated cardiomyopathy patient.
• The findings support the use of ivabradine in selected HIV-infected patients with CHF.
• Careful consideration and monitoring for drug interactions with antiretroviral agents are essential.